‘The depth and accuracy of patient identification using Velos Spring is unmatched’: CEO
The Fremont, CA-based company Velos, Inc. provides clinical research management software, and this week has released its Velos Spring analytics platform for clinical research.
John McIlwain, Velos CEO, thinks the need and demand for this type of product will be significant.
“There is considerable interest,” he told us. “And the economic value, for all but particularly for pharmaceutical companies and other industry sponsors, of getting more patients into suitable clinical trials more quickly is immense.”
McIlwain said there are three primary differences between Velos Spring and other similar offerings.
“First, we've reorganized and reclassified the source information to make it considerably more useful for clinical research. As a result, the depth and accuracy of patient identification using Velos Spring is unmatched in the literature,” he said.
Additionally, McIlwain said the company has taken a collaborative approach, one in which the user community can share the workload and crowdsource product development.
“Third, the few commercial competitors either charge a lot more, which impedes the adoption rate, or require data rights many are not comfortable with,” he added.
Velos Spring is a standalone product that works with any data source and can be integrated with all third-party systems.
The product also is integrated with the company’s patient recruitment and enrollment platform, Velos Volunteer, and Velos eResearch, which supports study fulfillment.
